NAU IB Capital (KOSDAQ:293580)
1,139.00
+2.00 (0.18%)
At close: Oct 20, 2026
NAU IB Capital Revenue
NAU IB Capital had revenue of 3.67B KRW in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to 22.28B, up 54.62% year-over-year. In the year 2025, NAU IB Capital had annual revenue of 20.64B with 46.41% growth. That makes NAU IB Capital the 34,798th largest company in the world by revenue and 2,226th in South Korea.
Revenue (ttm)
22.28B
Revenue Growth
+54.62%
P/S Ratio
4.85
Revenue / Employee
1.01B
Employees
22
Market Cap
108.13B
Revenue by Geography
- South Korea 11.24B 82.7%
- Overseas 2.35B 17.3%
Fiscal year ended Dec 31, 2025 See the full NAU IB Capital breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 20.64B | 6.54B | 46.41% |
| Dec 31, 2024 | 14.10B | -5.66B | -28.64% |
| Dec 31, 2023 | 19.76B | 5.83B | 41.86% |
| Dec 31, 2022 | 13.93B | -11.63B | -45.50% |
| Dec 31, 2021 | 25.56B | 15.71B | 159.48% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| KX Innovation | 366.70B |
| Cosmax Nbt | 335.18B |
| DK-Lok | 149.38B |
| Solborn | 125.03B |
| Jinro Distillers | 98.47B |
| OPTUS Pharmaceutical | 94.47B |
| FNS TECH. | 57.71B |
| CG MedTech | 51.20B |